These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26961797)

  • 21. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
    Pope B; Brown R; Luo XF; Gibson J; Joshua D
    Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental animal models of multiple myeloma].
    Miyakawa Y
    Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
    Gralewski JH; Post GR; van Rhee F; Yuan Y
    Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
    Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
    Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A murine model of human myeloma bone disease.
    Garrett IR; Dallas S; Radl J; Mundy GR
    Bone; 1997 Jun; 20(6):515-20. PubMed ID: 9177864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice.
    Murphy AJ; Sarrazy V; Wang N; Bijl N; Abramowicz S; Westerterp M; Welch CB; Schuetz JD; Yvan-Charvet L
    Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):751-8. PubMed ID: 24504733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
    Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
    J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.
    Imayoshi N; Yoshioka M; Chauhan J; Nakata S; Toda Y; Fletcher S; Strovel JW; Takata K; Ashihara E
    Biochem Biophys Res Commun; 2017 Mar; 484(2):262-268. PubMed ID: 28115161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
    Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
    Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
    Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
    Lee AH; Iwakoshi NN; Anderson KC; Glimcher LH
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9946-51. PubMed ID: 12902539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype.
    Bellamy WT; Mendibles P; Bontje P; Thompson F; Richter L; Weinstein RS; Grogan TM
    Cancer Chemother Pharmacol; 1996; 37(4):305-16. PubMed ID: 8548875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoblast-specific expression of MEF induces osteopenia through downregulation of osteoblastogenesis and upregulation of osteoclastogenesis.
    Seul KJ; Cho HS; Heo SH; Baek WY; Kim JE; Park EK; Choi JY; Ryoo HM; Cho JY
    J Bone Miner Res; 2011 Feb; 26(2):341-50. PubMed ID: 20715187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
    Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
    Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.
    Hamouda MA; Jacquel A; Robert G; Puissant A; Richez V; Cassel R; Fenouille N; Roulland S; Gilleron J; Griessinger E; Dubois A; Bailly-Maitre B; Goncalves D; Mallavialle A; Colosetti P; Marchetti S; Amiot M; Gomez-Bougie P; Rochet N; Deckert M; Avet-Loiseau H; Hofman P; Karsenti JM; Jeandel PY; Blin-Wakkach C; Nadel B; Cluzeau T; Anderson KC; Fuzibet JG; Auberger P; Luciano F
    J Exp Med; 2016 Aug; 213(9):1705-22. PubMed ID: 27455953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
    Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
    Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.